Dynavax's Q1 2025 Earnings Call: Key Contradictions on Shingles Study, Medicare Access, and Market Share Expectations

Shingles study readout and decision-making criteria, Medicare access and revenue impact, business development and strategic focus, HPV market share expectations, and market share expectations for HEPLISAV-B are the key contradictions discussed in Dynavax Technologies' latest 2025Q1 earnings call.



Revenue Growth and Market Share of HEPLISAV-B:
- Dynavax Technologies reported record net revenue of $65 million for HEPLISAV-B in Q1 2025, up 36% year-over-year.
- The growth was driven by increased market adoption and expanding market segments, particularly in the retail sector.

Strategic Pipeline Development:
- The company announced new programs in pandemic influenza and Lyme disease, leveraging its core adjuvant technology.
- This expansion is aimed at creating lower risk development pathways for products with significant commercial potential.

Shingles Vaccine Program Milestones:
- Dynavax is expected to report top-line data for the shingles vaccine program in Q3 2025, focusing on immunogenicity and tolerability.
- The purpose is to select the optimal antigen dosing schedule and formulation, with results anticipated to support progression into a pivotal efficacy trial.

Share Repurchase Program:
- Over 85% of Dynavax's $200 million share repurchase program has been executed as of May 5.
- This strategic move demonstrates confidence in the company's financial position and commitment to returning capital to shareholders.